Figures
Abstract
Background
G protein-biased mu-opioid receptor (MOR) agonists such as oliceridine and tegileridine were developed to reduce opioid-related side effects while keeping analgesic efficacy. The US FDA approved oliceridine in 2020 and China NMPA approved tegileridine in January 2024. Clinical development mainly focused on respiratory depression and gastrointestinal problems, but little...
This study presents an interesting development in the field of treating opioid addiction. The findings suggest that lofexidine may be a more effective option than current first-line treatments like methadone and buprenorphine. However, it's important to note the small sample size and the need for further research to confirm these results. Additionally, the study raises questions about the potential for new treatment options in addressing the ongoing opioid epidemic.
Patterns detected: None